We observed increased expression of the immune checkpoints PD-1, PD-L1, CTLA-4, and CD86 (CD28L), the expression levels of which associated with antitumor efficacy and tumor regression (Fig. 2B). The gene discussed is CTLA4; the disease is neoplasm.